Compare · ARGX vs IKT
ARGX vs IKT
Side-by-side comparison of argenx SE (ARGX) and Inhibikase Therapeutics Inc. (IKT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and IKT operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $57.45B, about 310.3x IKT ($185.2M).
- ARGX has been more active in the news (6 items in the past 4 weeks vs 3 for IKT).
- ARGX has more recent analyst coverage (25 ratings vs 8 for IKT).
- Company
- argenx SE
- Inhibikase Therapeutics Inc.
- Price
- -
- -
- Market cap
- $57.45B
- $185.2M
- 1M return
- +6.04%
- -
- 1Y return
- +2.20%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2020
- News (4w)
- 6
- 3
- Recent ratings
- 25
- 8
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Inhibikase Therapeutics Inc.
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It also develops IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- SEC Form 6-K filed by argenx SE
- argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities
- Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines
- Amendment: SEC Form SCHEDULE 13G/A filed by argenx SE
- argenx to Present at Upcoming Investor Conferences
- SEC Form 6-K filed by argenx SE
- argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
- argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026
- SEC Form 6-K filed by argenx SE
Latest IKT
- SEC Form 10-Q filed by Inhibikase Therapeutics Inc.
- Inhibikase Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Inhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent Activity
- Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026
- SEC Form 4 filed by Inhibikase Therapeutics Inc.
- SEC Form 3 filed by Inhibikase Therapeutics Inc.
- SEC Form 8-K filed by Inhibikase Therapeutics Inc.
- Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
- Chardan Capital Markets initiated coverage on Inhibikase Therapeutics with a new price target
- Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)